Juno Therapeutics Inc., a biopharmaceutical company developing cellular immunotherapies for the treatment of cancer, released additional data from the TRANSCEND study of JCAR017 (lisocabtagene maraleucel; liso-cel) in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in a presentation at the 59th American Society of Hematology Annual Meeting and Exposition.
Eating less sugar could protect the microbiome during antibiotic treatment, according to a study led by researchers at City of Hope. The study followed patients with blood cancer who were going through an intensive treatment called allogeneic hematopoietic cell transplant. This population is at particularly high risk for severe gut microbiome disruption and associated side effects.
